







COVID-19 Vaccines Approved for Use in Canada: mRNA vaccines

COVID-19 Formulations	Moderna (Spikevax™)	Moderna (Spikevax™) <i>Bivalent BA 4/5</i>		Pfizer (Comirnaty™)	Pfizer (Comirnaty™) <i>Bivalent BA 4/5</i>	Pfizer (Comirnaty™) <i>Bivalent BA 4/5</i>
Vaccine Type	mRNA	mRNA bivalent		mRNA	mRNA bivalent	mRNA bivalent
Cap and Label Colour						
	Royal Blue cap/ Purple label	Royal Blue cap/ grey label (+Bivalent)		Maroon cap and label	Orange cap and label (+Bivalent)	Grey cap and label (+Bivalent)
Formats available	Multidose (0.10 mg/ml) 10 doses/vial	Multidose (0.10 mg/ml) 10 doses/vial	Multidose (0.10 mg/ml) 5 doses/vial	Multidose 10 doses/vial	Multidose 10 doses/vial	Multidose 6 doses/vial
Authorized Age Group	6 months to 5 years	6 months to 11 years	12 years and older	6 months to 4 years	5 to 11 years	12 years and older
Dose and Injection Volume	0.25ml 25 mcg	0.25ml 25 mcg	0.5ml 50 mcg	0.2ml 3 mcg	0.2ml 10 mcg	0.3ml 30 mcg
Dilution	None	None		2.2ml/vial	1.3ml/vial	None
Routine schedule (primary series) ^o	2 doses at least 8 weeks apart* (preferred product for immunocompromised)	2 doses at least 8 weeks apart* (generally preferred product for immunocompromised)		3 doses at least 8 weeks between each dose*	2 doses at least 8 weeks apart*	2 doses at least 8 weeks apart* (generally preferred product for age 12 to 29 years)
Booster Dose	N/A	6 months ** (only authorized for age 6 years and older)		N/A	6 months**	6 months**
Date Authorized (primary dose)	July 14/22	June 9/23 (off-label use based on NACI's interim guidance)		Sept 9/22	July 6/23	July 6/23
Date Authorized (booster dose)	N/A	Sept 1/22		N/A	Dec 9/22	Oct 7/22
Product Monograph	For links to the Covid-19 vaccine product monographs and resources refer to: Province of Manitoba Information for Health Care Professionals (gov.mb.ca)					

^o NACI has provided recommendations considering the currently available bivalent Omicron-containing mRNA COVID-19 vaccines; when mRNA COVID-19 vaccines are used for the primary series, bivalent Omicron-containing vaccines can be used in individuals 6 months of age and over.

*For those who are moderately to severely immunocompromised, an additional dose is recommended, usually with an 8 week interval between each dose. Moderna Spikevax™ vaccines are generally the preferred product for immunocompromised individuals. Pfizer Comirnaty™ vaccines are generally the preferred product for those age 12 to 29 years receiving their primary series due to lower risk of myocarditis/pericarditis. For individuals age 12 to 29 who are immunocompromised, Moderna Spikevax™ vaccines may be considered based on clinical judgement.

**Recommended minimum interval for optimum immune response is 6 months after primary series or previous booster dose as vaccine effectiveness increases with a longer duration between doses.

COVID-19 Vaccines Approved for Use in Canada: non-mRNA vaccines	
COVID-19 Formulations	Novavax (Nuvaxovid™)
Vaccine Type	Protein Subunit
Cap Colour	 Blue Cap
Formats Available	Multidose 10 doses/vial
Authorized Age Group	12 years and older
Dose and Injection Volume	0.5ml 5 mcg
Dilution	None
Routine schedule (primary series)	2 Doses given 8 weeks apart
Booster Dose	18 years and older: 0.5 ml (5 mcg) 6 months (see ** note on previous page)
Date Authorized (primary dose)	Feb 17/22
Date Authorized (booster dose)	Nov. 17/22
Product Monograph	Province of Manitoba Information for Health Care Professionals (gov.mb.ca)

Influenza and Pneumococcal Vaccines Approved for Use in Canada: 2022-2023					
Formulations	Fluzone® Quadrivalent	FluLaval® Tetra	Alfurina® Tetra	Fluzone® High Dose	Pneumovax®23 (Pneu-P-23)
Vaccine Type	IIV4-SD	IIV4-SD	IIV4-SD	IIV4-HD	Pneumococcal polysaccharide 23-valent
Formats Available	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	5.0 mL multidose vial (10 doses/vial)	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	0.7 ml Single dose prefilled syringe	0.5 ml single dose prefilled syringe <i>or</i> 0.5 ml single dose vial
Authorized Age Group	6 months and older	6 months and older	5 years and older	65 years and older	65 years and older
Injection Volume	0.5ml	0.5ml	0.5ml	0.7ml	0.5ml
Dose Schedule	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	**1 or 2 doses: children 5 years to less than 9 years 1 dose: ≥ 9 years	1 dose	1 dose
Product Monograph	Fluzone PM	FluLaval PM	Afluria PM	High Dose PM	Pnuemo PM

* Children 6 months to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.

**Children 5 years to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.